Overview
ABBV market data
Price History
ABBV price chart
Valuation & Profitability
- P/E (TTM)
- 124.88 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $2.38 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.27 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 269.3% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $184.90 – $261.64 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $453.9K · P/B 94.44 · P/S 7.23.
Company news
Netflix, AbbVie, Cerebras Systems And An Energy Stock On CNBC’s ‘Final Trades’Benzinga · Jul 24, 2026, 11:53 AM
Two Years to Build or Pay 200% — Which US Pharma Stocks Win?Benzinga · Jul 24, 2026, 10:25 AM
iShares Global Healthcare ETF vs VanEck Biotech ETF: Which ETF Is Better for Profiting With Healthcare in 2026?The Motley Fool · Jul 23, 2026, 8:15 PM
Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)Globenewswire Inc · Jul 23, 2026, 8:15 PM
GenMab A/S And AbbVie To Submit Data To Peer-Reviewed Medical Journal For Already-Released Phase 3 Trial Data Evaluating Epcoritamab For Adults With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma Who Were Ineligible For Autologous Stem Cell TransplantationBenzinga · Jul 23, 2026, 8:10 PM
CNBC Halftime Report Final Trades: AbbVie, Transocean, Cerebras Systems, NetflixBenzinga · Jul 23, 2026, 5:01 PM
Which Is the Better Healthcare ETF: First Trust's High-Conviction FBT or Vanguard's Low-Cost VHT?The Motley Fool · Jul 23, 2026, 1:15 PM
Which ETF Is Healthier for Your Portfolio: Vanguard Health Care ETF or iShares Pharmaceuticals ETF?The Motley Fool · Jul 22, 2026, 9:15 PM
As Healthcare Rallies Is the Vanguard Health Care ETF of the Invesco Pharmaceuticals ETF the Better Fund for 2026?The Motley Fool · Jul 22, 2026, 8:15 PM
Synchrony Financial To Rally Around 25%? Here Are 10 Top Analyst Forecasts For WednesdayBenzinga · Jul 22, 2026, 12:06 PM